Search clinical trials for: Pembrolizumab - anti-PD-1 antibody

Total 7271 results

Changzhou No.2 People's Hospital

Not yet recruiting

γδ T-PD-1 Ab Cells in the Treatment of Advanced Solid Tumors

Advanced Solid Tumor
Sun Yat-sen University

Recruiting

Anti-PD-1 Immunotherapy Combined With SBRT for Patients With Oligometastatic ESCC

Esophageal Squamous Cell Carcinoma | Oligometastatic Disease

China
The Second Hospital of Hebei Medical University

Recruiting

Safety and Efficacy of TRPP Therapy in Glioblastoma Multiforme

Glioblastoma Multiforme

China
Peking University First Hospital
YiZhou International Cancer Hospital

Unknown

Combination of Proton Therapy With Immunotherapy in Multiple Metastases Cancer (PI-MMC)

Neoplasm Metastasis | Immunotherapy | Proton Therapy
Second Military Medical University

Unknown

Immunotherapy Using Pluripotent Killer-Programmed Cell Death 1 (PIK-PD-1) Cells for the Treatment of Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

China
Bio-Thera Solutions
Sun Yat-sen University

Recruiting

BAT7104 Injection in Patients With Advanced Malignant Tumors.

Advanced Malignant Tumor

China
Shanghai Zhongshan Hospital

Recruiting

Anti-PD-1/PD-L1 Antibodies Plus Pegylated Interferon Alfa-2b Treatment in Patients With Advanced-Stage HCC

Hepatocellular Carcinoma

China
Jinling Hospital, China

Recruiting

A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy

Renal Cell Carcinoma | Radiotherapy | Immune Checkpoint Inhibitor

China
Fudan University

Recruiting

Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE)

Rectal Cancer

China
Ruijin Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer (N-PRC)

Rectal Cancer | Locally Advanced
Second Affiliated Hospital, School of Medicine,...

Recruiting

Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCORE Ⅱ） (neoSCORE Ⅱ)

Squamous Cell Non-small Cell Lung Cancer

China
China Medical University, China

Recruiting

PD-1 Antibody + Apatinib Mesylate in 2+ Line Serum AFP-elevated Gastric Adenocarcinoma

Gastric Cancer | AFP

China
University Health Network, Toronto

Not yet recruiting

A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma

Melanoma (Skin)

Canada
Hunan Province Tumor Hospital

Completed

The Prediction Biomarkers of Survival Outcome for Severe Immune-related Hepatitis

Lung Cancer

China
Tongji Hospital
Wuhan University; Sun Yat-sen University; Wuhan Union Hospital, China

Suspended

Radiotherapy Combined With Immunotherapy for Brain Metastases of Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

China
Northwestern University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; Seagen Inc.

Withdrawn

Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma

Recurrent Angioimmunoblastic T-Cell Lymphoma | Refractory Angioimmunoblastic T-Cell Lymphoma | Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified | Recurrent Enteropathy-Associated T-Cell Lymphoma | Recurrent Follicular T-Cell Lymphoma | Recurrent Hepatosplenic T-Cell Lymphoma | Recurrent... and other conditions

United States
Northwestern University
National Cancer Institute (NCI); Pfizer

Terminated

Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | HER2/Neu Positive | Progesterone Receptor Negative | Breast Carcinoma Metastatic in the Brain

United States
Canadian Cancer Trials Group
Melanoma and Skin Cancer Trials Limited

Recruiting

Duration of Anti-PD-1 Therapy in Metastatic Melanoma (STOP-GAP)

Unresectable/Metastatic Melanoma

Canada, Australia
Dragonboat Biopharmaceutical Company Limited
West China Hospital

Recruiting

An Exploratory Clinical Study of LDP Combined With CDP1 in Patients With Advanced Malignant Tumor

Advanced Malignant Tumor

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Suspended

A Study of First-line JS001 and Nab-paclitaxel Versus Palcelbo and Nab-Paclitaxel in Participants With Advanced Recurrent or Metastatic TNBC

Triple Negative Breast Cancer

China
Dragonboat Biopharmaceutical Company Limited
Fudan University

Recruiting

the Efficacy and Safety of LDP in Patients With Urinary and Male Genital Tumors

Bladder Cancer | Renal Carcinoma | Advanced Penile Carcinoma

China
Fundación GECP

Not yet recruiting

Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free. (ARIAN)

Lung Diseases | Carcinoma, Non-Small-Cell Lung | Resectable Lung Non-Small Cell Carcinoma

Spain
Shanghai General Hospital, Shanghai Jiao Tong University...

Recruiting

Clinical Study of Multi-mode Thermal Ablation for the Treatment of Pancreatic Cancer With Liver Metastasis

Pancreatic Cancer

China
Roswell Park Cancer Institute
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Completed

Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery

Recurrent Colorectal Carcinoma | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer

United States
Peking University Cancer Hospital & Institute
Innovent Biologics (Suzhou) Co. Ltd.

Completed

HAIC Combined Sintilimab for Liver Metastasis From Esophageal Squamous Cell Carcinoma

Liver Metastases | Esophageal Squamous Cell Carcinoma | Hepatic Arterial Infusion Chemotherapy

China
Lei Li

Recruiting

Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy: Multi-Center Trial

Chemotherapy | Recurrent Cervical Carcinoma | Immune Checkpoint Inhibitors | Anti-PD-1 Antibody | Persistent Advanced Cervical Carcinoma | Albumin-bound Paclitaxel

China
University of California, Davis
National Cancer Institute (NCI); IO Biotech

Recruiting

IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer

Stage 0a Bladder Cancer AJCC v8 | Stage 0is Bladder Cancer AJCC v8 | Stage I Bladder Cancer AJCC v8 | High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma

United States
Second Affiliated Hospital of Soochow University

Recruiting

A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer

Advanced Solid Tumor | Refractory Tumor

China
National Cancer Institute (NCI)

Not yet recruiting

Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma

Stage II Squamous Cell Carcinoma of the Head and Neck | Stage III Squamous Cell Carcinoma of the Head and Neck | Stage IV Squamous Cell Carcinoma of the Head and Neck

United States
Wuxi People's Hospital

Recruiting

Clinical Efficacy of Tumour Treatment Vaccine (TTV) Combined With PD-1 in the Treatment of Relapsed Refractory Advanced Solid Tumours

Cancer | PD-L1 Gene Mutation

China
Buzzard Pharmaceuticals
Baylor Research Institute

Recruiting

Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors

Solid Tumor, Adult

United States
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of BL-M07D1+PD-1 Monoclonal Antibody and BL-M07D1+PD-1 Monoclonal Antibody+Capecitabine in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma

HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma

China
Sir Run Run Shaw Hospital

Recruiting

Nodes-sparing Short-course Radiation Combined With CAPOX and Tislelizumab for MSS Middle and Low Rectal Cancer (mRCAT)

Low Rectal Cancer

China
Niels Junker
Karolinska University Hospital; Oslo University Hospital; Aarhus University Hospital

Recruiting

Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients (PROPANE)

Soft Tissue Sarcoma Adult | Angiosarcoma | Undifferentiated Pleomorphic Sarcoma

Norway, Sweden, Denmark
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer

Stage IV Breast Cancer AJCC v6 and v7 | Metastatic Breast Carcinoma

United States
Megan Daly, MD
EMD Serono

Completed

UCDCC#270: Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients

Metastatic Non-small Cell Lung Cancer (NSCLC)

United States
Changhai Hospital

Not yet recruiting

DV Combined With PD-1 and Platinum-based First-line Treatment in Patients With HER2 IHC2+/3+ ESCC

HER-2 Protein Overexpression | Esophageal Squamous Carcinoma
Zhejiang University

Active, not recruiting

Anti-PD-1 Antibody Plus DEB-TACE for BCLC Stage A/B HCC

Hepatocellular Carcinoma

China
Fudan University

Recruiting

The Combination of Immunotherapy and Neoadjuvant Short-course Radiotherapy in Early Rectal Cancer (TORCH-E） (TORCH-E)

Early Low Rectal Cancer

China
Fudan University

Recruiting

Short-course Radiotherapy Based TNT Combined With PD-1 Inhibitor for Locally Advanced Rectal Cancer (TORCH)

Locally Advanced Rectal Cancer

China
Shanghai Zhongshan Hospital

Not yet recruiting

Synergistic Effects of PD-1 Antibody and Chemotherapy Followed by Surgery in Limited-metastatic G/GEJ Adenocarcinoma (ROSETTE)

Gastric Cancer | GastroEsophageal Cancer

China
Sinocelltech Ltd.

Terminated

SCT-I10A or Placebo Plus Docetaxel With Previously Treated Squamous Cell Non-small Cell Lung Cancer

Squamous-cell Non-Small-cell Lung Cancer

China
Qilu Pharmaceutical Co., Ltd.

Terminated

QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer

Cervical Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC

Triple Negative Breast Cancer

China
Fujian Cancer Hospital

Unknown

PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer

Advanced Gastric Adenocarcinoma

China
RenJi Hospital
Shanghai Zhongshan Hospital; Ruijin Hospital

Recruiting

A Study of Cadonilimab（AK104） Plus Lenvatinib in Previous Immunotherapy Treated Advanced/Metastatic Clear Cell Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma、Resistance to Immunotherapy

China
Shanghai Zhongshan Hospital

Not yet recruiting

PD-1/PD-L1 Inhibitors and Anti-angiogenic Therapy Combined With/Without TACE/HAIC in Patients With BCLC B/C Hepatocellular Carcinoma Beyond Up-to-7

Hepatocellular Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Neoadjuvant Tirellizumab Combined With Chemotherapy for Early Oral Squamous Cell Carcinoma(HNC-SYSU-004)

Oral Cancer | PD-1

China
Sun Yat-sen University
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

PD-1 Antibody and Sapropterin Dihydrochloride in Patients With PDAC

Pancreatic Adenocarcinoma Metastatic

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs

Breast Cancer | Triple-Negative Breast Cancer

China

Search clinical trials for: Pembrolizumab - anti-PD-1 antibody

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Colombia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations